203 results on '"Jha A. K."'
Search Results
2. Role of MBD4 Mutation in Neoplastic Evolution of Acute Myeloid Leukemia
3. Clinical and Mechanistic Relationship of T -Cell Large Granular Lymphocytic Leukemia ( TLGL) and monoclonal Gammopathy of Undetermined Significance (MGUS)
4. Demonstration That Loss of TET2 Impairs DNA Mismatch Repair Resulting in Clonally Restricted Genomic Instability
5. Heightened Endoplasmic-Reticulum Stress Is a Targetable Vulnerability of Malignant Plasma Cells in Multiple Myeloma
6. Therapeutic Targeting of TET-Dioxygenase Deficiency in Myeloid Malignancies
7. Genomic Landscape of PHD Finger Protein 6 (PHF6) Mutant Myeloid Neoplasia
8. A Novel Approach to Induce ATRA Mediated Differentiation in NPM1 Mutant Acute Myeloid Leukemia
9. The Drive to Acquire Biallelic Hits Inversely Correlates with the Functional Impact of the Primary TP53 Lesion: The Complexity of TP53 Role Assessment
10. Epigenetic Enzyme Mutations in Myeloid Malignancies Are Selected By Chromatin-Remodeling Requirements That Vary By Lineage- and Maturation-Stage
11. Spectrum of Molecular Modes of Immune Escape in Idiopathic Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
12. Myelodysplastic Syndromes: A More Global 5-Hydroxymethylcytosine Deficiency Disorder Than Suggested By the Presence of TET2 Mutations
13. Germline MPO Variants Predispose to Myeloid Neoplasia: Potential Mechanisms Suggested By In Vivo and in Vitro Studies
14. A Personalized Clinical-Decision Tool to Improve the Diagnostic Accuracy of Myelodysplastic Syndromes
15. Methyl-CpG Binding Domain Protein MBD2 Is a Targetable Vulnerability in TET2 Mutant Myeloid Neoplasia
16. Loss of Function MBD4 Mutation Impairs DNA Repair in Association with TET2 in Acute Myeloid Leukemia
17. Personalized Transcriptomic Analyses Identify Unique Signatures That Correlate with Genomic Subtypes in Acute Myeloid Leukemia (AML) Using Explainable Artificial Intelligence
18. TET2 Inhibitory Effects of Eltrombopag Contribute Its Hematopoietic Activity
19. Multicenter Validation of a Personalized Model to Predict Hypomethylating Agent Response in Myelodysplastic Syndromes (MDS)
20. A Novel Therapeutic Strategy for Preferential Elimination of Multiple Myeloma Cells By Targeting Protein Disulfide Isomerase
21. Inhibition of Critical DNA Dioxygenase Activity in IDH1/2 Mutant Myeloid Neoplasms
22. Impact of HLA Evolutionary Divergence on Clinical Features of Patients with Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
23. Genotype-Phenotype Correlations in Patients with Myeloid Malignancies Using Explainable Artificial Intelligence
24. Venetoclax Inhibition of Pyrimidine Synthesis Guides Methods for Integration with Decitabine or 5-Azacytidine That Are Non-Myelosuppressive
25. Role of Oligoadenylate Synthetases in Myeloid Neoplasia
26. Clinical and Mechanistic Relationship of T-Cell Large Granular LymphocyticLeukemia (TLGL) andmonoclonal Gammopathy of Undetermined Significance(MGUS)
27. Germline loss-of-function SAMD9 and SAMD9L alterations in adult myelodysplastic syndromes
28. TET Dioxygenase Inhibition As a Therapeutic Strategy in TET2 Mutant Myeloid Neoplasia
29. Eltrombopag Creates a Transient Chemical Phenocopy of TET2 Loss of Function That Contributes to Hematopoietic Precursor Expansion
30. Fatty Acid Binding Protein FABP5: A Novel Therapeutic Target in Acute Myeloid Leukemia
31. Geno-Clinical Model for the Diagnosis of Bone Marrow Myeloid Neoplasms
32. Predicting Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes (MDS) Using Artificial Intelligence (AI)
33. MPO as a Novel Susceptibility Gene in Myeloid Malignancies
34. Reversible TET Inhibitor As a Hematopoietic Stem Cell Booster: A Novel Strategy to Improve Stem Cell Function
35. TET2 Loss Accelerates Leukemogenesis By Disrupting Mismatch Repair Proteins
36. Somatic Mutations in Therapy-Related Myeloid Neoplasms Are Influenced By Therapeutic Modality and Clonal Hematopoiesis of Indeterminate Potential
37. Opposing Pathogenesis of Germline SAMD9/SAMD9L Variants in Adult Myelodysplastic Syndrome (MDS)
38. A First-in-Class Inhibitor of ISWI-Mediated (ATP-Dependent) Transcription Repression Releases Terminal-Differentiation in AML Cells While Sparing Normal Hematopoiesis
39. Lessons from Nature: A Novel Class of TET Inhibitors for TET2 Mutant Associated Diseases
40. Targeting NAD+ Modulating Enzymes to Improve HSC Function in Aging and Bone Marrow Failure
41. Differences in Genomic Patterns between African Americans and Whites with Acute Myeloid Leukemia
42. Genomic Biomarkers Predict Response/Resistance to Lenalidomide in Non-Del(5q) Myelodysplastic Syndromes
43. Molecular Characterization of Acute Myeloid Leukemia Patients with Normal Karyotype
44. Targeting Antagonists of Retinoic Acid Signaling in Acute Myeloid Leukemia
45. Geno-Clinical Model to Aid in the Diagnosis of Myelodysplastic Syndrome (MDS) Versus Chronic Myelomonocytic Leukemia (CMML)
46. Modulation of TET2 Activity By Ascorbic Acid and Factors Affecting Lysine Acetylation
47. Biallelic TET2 Inactivation in Myeloid Neoplasia: From Clonal Hierarchy to Clinical Phenotypes
48. The Mechanisms By Which Mutant-NPM1 Uncouples Differentiation from Proliferation Are Reversed By Several Drugs, Enabling Rational Multi-Component Non-Cytotoxic Differentiation Therapy
49. An unusual cause of ascites
50. BCOR Mutations in Myelodysplastic Syndromes (MDS): Mutation Characteristics Impact Clinical Outcomes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.